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| INTRODUCTION
Prostate cancer is among the most frequently diagnosed malignancies in men worldwide. 1 Skeletal metastases occur in approximately 80% of patients with advanced prostate cancer, for which there is no curative treatment. 2, 3 Within the tumor microenvironment, chemokines and their receptors influence growth and metastasis. 4, 5 For example, C-C motif ligand 2 (CCL2) is present in the microenvironment of many cancers and upregulated in prostate cancer cells. 6 We previously reported that bone stromal cells and SaOS-2 osteoblast-like cells promoted prostate cancer metastasis through activation of transforming growth factor (TGF)-b1, 7 and that CCL2, CCL4
and CCL22 were associated with prostate cancer progression.
androgen receptor (AR) signaling. 15, 16 
| Conditioned medium
Cells were seeded into 6-well culture plates and allowed to adhere overnight. The next day, the medium was aspirated and replaced with 2 mL of medium containing 5% FBS. The supernatant was removed 48 hours later, centrifuged at 300 g for 10 minutes and collected as conditioned medium (CM). 
| Co-culture assays

| Cell migration assay
The cell migration assay was performed using 8. plates were incubated at 37°C and 5% CO 2 for 48 hours.
| Western blot assay
Cell lysates were prepared with M-PER Mammalian Protein Extraction Reagent (Thermo Fisher Scientific). The soluble lysate (5-10 lg)
was mixed with LDS sample buffer and sample reducing agent and was resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The proteins were transferred to nitrocellulose
membranes. The membranes were blocked with 1% gelatin in 0.05%
Tween in Tris-buffered saline for 1 hour at room temperature (RT) and then incubated overnight at 4°C with anti-CCR5 and anti-AR primary antibodies following the kit manufacturer's instructions.
Membranes were washed 3 times before incubation with HRP-conjugated anti-rabbit secondary antibodies for 1 hour at RT. Protein loading was determined with an anti-GAPDH control antibody. Protein bands were read using SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific).
| Human cytokine antibody array
Cytokines were assayed in CM collected from LNCaP, BDSC and
BmetSC cell cultures using a Human Cytokine Array kit (ARY017, R&D Systems) following the manufacturer's instructions. ( Figure 4D ).
| C-C motif ligand 5 did not induce the migration of LNCaP cells after androgen receptor knockdown
C-C motif ligand 5 is known to inhibit AR nuclear translocation and to downregulate androgen signaling in prostate cancer cells. 15 Recent studies clarified that downregulation of AR not only inhibited cell proliferation but also promoted cell migration through epithelial-mesenchymal transition. 
| DISCUSSION
The AR is a primary driver of prostate cancer progression, and it is strongly expressed before development of castration resistance. tissues, suggesting that CCL5 specifically acts on cancer cells. Therefore, targeting CCR5 might be a novel treatment for prostate cancer bone metastasis as well as CCL5. Furthermore, the CCL5-CCR5 axis may be a novel biomarker for prostate cancer. The limitations of using a prostate-specific antigen alone as a biomarker for prostate cancer, and the need for more specific and effective biomarkers, have been discussed elsewhere. 29, 30 Previously, we reported that the serum CCL2 level in patients with prostate cancer was predictive of the time taken by tumors to become castration-resistant and of overall and prostate cancer-specific survival. 31 Additional clinical evidence is needed to show the superiority of the CCL5-CCR5 axis over the CCL2-CCR2 axis as a prostate cancer biomarker.
There are some points to be discussed carefully in this study.
Chemokine array showed high intensity in IL-8 and CXCL12.
Although we did not focus on these chemokines because no significant difference between BDSC and BmetSC were observed on array, they may exert some effects on prostate cancer cells cooperating with other functional molecules. For instance, CXCL12-mediated activation of ERK or AKT pathways is modulated by PTEN status. 32 Next, the effect of CCL5 is less than SiAR. As Figures 4A and 5C show, the effect of CCL5 on migration was less than SiAR. More- To our knowledge, this is the first study to show that CCL5 was expressed in bone stromal cells and that the CCL5-CCR5 axis contributed to prostate cancer cell migration. The CCL5-CCR5 axis, which is activated in prostate cancer bone metastasis, may be a novel therapeutic target and a potential biomarker for prostate cancer.
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